Showing 2051-2060 of 3355 results for "".
New Products
https://practicaldermatology.com/columns/new-products/new-products/21262/The Molecular Era in Melanoma Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-molecular-era-in-melanoma-treatment/21296/Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.Analyzing Risk Factors for Subsequent Primary Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-risk-factors-for-subsequent-primary-melanomas/21429/SPF Recommendations: Should They Change?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/spf-recommendations-should-they-change/21475/What is the minimum SPF dermatologists should be recommending to their patients?Charging Toward Stage 2 of Meaningful Use
https://practicaldermatology.com/topics/practice-management/charging-toward-stage-2-of-meaningful-use/21467/As the next stage of the Federal EHR incentive program is set to begin, the forecast remains uncertain.Protect Yourself Against System Breaches and Errors
https://practicaldermatology.com/topics/practice-management/protect-yourself-against-system-breaches-and-errors/21579/New reports of cyber-terrorism highlight the importance of EHR security.New Products and Pharmacologic Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21633/Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20371/